SIK1 and cancer: This could be easily tested by using clinically approved anticancer drugs dasatinib and bosutinib that inhibit SIK isoforms in addition to their intended targets in a number of cancer cell types, including multiple Burkitt’s lymphoma (BL) cell lines42,55–57, hepatocellular carcinoma58 and prostate carcinoma cells59–61 that have been reported to undergo apoptosis in response to TGFβ.